Photo by nci from unsplash
N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and treatment of bleeds in haemophilia A patients. Click to show full abstract
N8‐GP (turoctocog alfa pegol) is an extended half‐life glycoPEGylated recombinant factor VIII (FVIII) product developed for the prevention and treatment of bleeds in haemophilia A patients.
Keywords:
glycopegylated recombinant;
extended half;
life glycopegylated;
haemophilia first;
half life
Journal Title: Haemophilia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!